

AGENDA

08:00 AM Onwards Registration
 08:25 AM - 08:30 AM Welcome Note & Setting the Context

Session 1:

08:30 AM - 08:50 AM Gold Standard molecular test for diagnosis and monitoring in hematology patients
 08:50 AM - 09:10 AM Treatment decisions based on cytogenetics and molecular studies in AML patients
 09:10 AM - 09:30 AM Treatment decisions based on cytogenetics and molecular studies in ALL patients
 09:30 AM - 09:50 AM Four Practice changing abstracts for EHA 2026
 09:50 AM - 10:20 AM Pediatric Thrombocytopenia - Unmasking Inherited Disorders - A Case Based Discussion

Session 2:

10:20 AM - 11:05 AM Panel Discussion - Indications for BMT & CAR-T in Hemato oncology patients - 3 cases
 11:05 AM - 11:25 AM Journey of Oncology patients in the last 10 years - Personalized treatment decision in oncology patients
 11:25 AM - 11:45 AM Treatment decision based on cytogenetics & molecular studies in Multiple Myeloma
 11:45 AM - 12:05 PM Evolution of Molecular studies in hematology patients
 12:05 PM - 12:35 PM Evolution of molecular studies in Hematology: Shift towards precision Hematology
 12:35 PM - 01:05 PM Case Based Discussion: Driving Change in 1L DLBCL
 01:05 PM - 02:00 PM LUNCH BREAK
 02:00 PM - 02:20 PM Treatment decision based on cytogenetics & molecular studies in Lymphoma Patients
 02:20 PM - 02:40 PM Maintenance therapy in Hemato-oncology patient based on cytogenetic & Molecular studies
 02:40 PM - 03:00 PM Treatment decision based on cytogenetics & Molecular studies in CLL patients
 03:00 PM - 04:00 PM TBA
 04:00 PM - 04:20 PM Ethical, Legal and Social Issues with Whole Genome Sequencing in Today's Times
 04:20 PM - 04:40 PM The role of the morohologist in the era of molecular diagnostics
 04:40 PM - 04:55 PM Genetic diagnosis and clinical relevance in IBMFS
 04:55 PM Vote of Thanks & Closing